A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,500 shares of ACRS stock, worth $13,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,500
Previous 13,200 73.48%
Holding current value
$13,300
Previous $14,000 78.57%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.12 - $1.4 $571,926 - $714,908
-510,649 Reduced 58.35%
364,567 $411,000
Q2 2024

Aug 14, 2024

SELL
$1.01 - $1.36 $55,334 - $74,510
-54,787 Reduced 5.89%
875,216 $962,000
Q1 2024

May 15, 2024

SELL
$0.92 - $1.44 $4.1 Million - $6.42 Million
-4,458,786 Reduced 82.74%
930,003 $1.15 Million
Q4 2023

Feb 14, 2024

BUY
$0.64 - $6.49 $1.3 Million - $13.2 Million
2,031,549 Added 60.51%
5,388,789 $5.66 Million
Q3 2023

Nov 14, 2023

BUY
$6.56 - $10.95 $4.88 Million - $8.15 Million
744,166 Added 28.48%
3,357,240 $23 Million
Q2 2023

Aug 14, 2023

SELL
$7.89 - $10.64 $3.9 Million - $5.26 Million
-494,690 Reduced 15.92%
2,613,074 $27.1 Million
Q1 2023

May 15, 2023

BUY
$7.07 - $17.95 $14.4 Million - $36.5 Million
2,032,724 Added 189.08%
3,107,764 $25.1 Million
Q4 2022

Feb 14, 2023

SELL
$14.33 - $18.37 $621,592 - $796,835
-43,377 Reduced 3.88%
1,075,040 $16.9 Million
Q3 2022

Nov 14, 2022

BUY
$13.07 - $18.22 $2.16 Million - $3.01 Million
165,345 Added 17.35%
1,118,417 $17.6 Million
Q2 2022

Aug 15, 2022

SELL
$10.16 - $17.08 $194,340 - $326,706
-19,128 Reduced 1.97%
953,072 $13.3 Million
Q1 2022

May 16, 2022

SELL
$9.74 - $17.92 $385,431 - $709,130
-39,572 Reduced 3.91%
972,200 $16.8 Million
Q4 2021

Feb 14, 2022

SELL
$12.27 - $18.49 $636,138 - $958,614
-51,845 Reduced 4.87%
1,011,772 $14.7 Million
Q3 2021

Nov 15, 2021

SELL
$13.38 - $18.8 $2.19 Million - $3.08 Million
-163,776 Reduced 13.34%
1,063,617 $19.1 Million
Q2 2021

Aug 16, 2021

SELL
$17.08 - $29.6 $1.71 Million - $2.96 Million
-99,956 Reduced 7.53%
1,227,393 $21.6 Million
Q1 2021

May 17, 2021

BUY
$5.86 - $27.73 $7.54 Million - $35.7 Million
1,286,007 Added 3110.66%
1,327,349 $33.4 Million
Q4 2020

Feb 16, 2021

BUY
$2.65 - $7.61 $43,030 - $123,571
16,238 Added 64.68%
41,342 $267,000
Q3 2020

Nov 16, 2020

BUY
$1.5 - $2.71 $37,656 - $68,031
25,104 New
25,104 $65,000
Q2 2020

Aug 14, 2020

SELL
$1.04 - $1.73 $53,300 - $88,662
-51,250 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$0.75 - $2.18 $18,359 - $53,364
24,479 Added 91.44%
51,250 $53,000
Q4 2019

Feb 14, 2020

SELL
$1.02 - $1.97 $48,922 - $94,487
-47,963 Reduced 64.18%
26,771 $51,000
Q3 2019

Nov 14, 2019

BUY
$0.79 - $2.47 $33,401 - $104,434
42,281 Added 130.28%
74,734 $80,000
Q2 2019

Aug 14, 2019

SELL
$2.13 - $7.06 $333,106 - $1.1 Million
-156,388 Reduced 82.81%
32,453 $71,000
Q1 2019

May 15, 2019

SELL
$5.63 - $7.84 $2.06 Million - $2.87 Million
-365,497 Reduced 65.93%
188,841 $0
Q4 2018

Feb 14, 2019

SELL
$6.3 - $15.4 $2.07 Million - $5.05 Million
-328,026 Reduced 37.18%
554,338 $4.1 Million
Q3 2018

Nov 13, 2018

BUY
$14.38 - $20.89 $203,246 - $295,259
14,134 Added 1.63%
882,364 $0
Q2 2018

Aug 10, 2018

SELL
$16.46 - $20.33 $470,871 - $581,580
-28,607 Reduced 3.19%
868,230 $0
Q1 2018

May 11, 2018

BUY
$17.08 - $25.64 $12.8 Million - $19.2 Million
748,422 Added 504.28%
896,837 $15.7 Million
Q4 2017

Feb 09, 2018

SELL
$21.47 - $27.8 $2.01 Million - $2.6 Million
-93,601 Reduced 38.68%
148,415 $3.66 Million
Q3 2017

Nov 09, 2017

BUY
$23.02 - $28.8 $5.57 Million - $6.97 Million
242,016
242,016 $6.25 Million

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $253M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.